AZN issues correction: disregard erroneous 26 Aug TR-1, see 21 Aug notice

Rhea-AI Filing Summary

AstraZeneca issued a correction to a previously announced TR-1 notification. The Company states that a TR-1 submitted by The Capital Group Companies, Inc. and announced on 26 August 2025 was provided in error and should be disregarded. Shareholders are instead directed to the TR-1 notification relating to Capital Group that AstraZeneca announced on 21 August 2025, available via the referenced RNS link. The notice is administrative and clarifies which prior disclosure is the valid notification.

Positive

• Correction issued promptly to clarify the proper TR-1 disclosure and reduce investor confusion
• Directs investors to the earlier, correct TR-1 announced on 21 August 2025

Negative

• An erroneous TR-1 announcement was published on 26 August 2025, requiring a correction

Insights

Corporate Governance Expert

TL;DR: Administrative correction clarifying which institutional holding disclosure is valid; no new holdings data provided.

The filing corrects an earlier TR-1 announcement by advising investors to disregard the 26 August 2025 notice and rely on the 21 August 2025 TR-1 for The Capital Group Companies, Inc. This is a procedural clarification rather than a substantive update to shareholdings in this Form 6-K. It eliminates potential confusion arising from multiple TR-1 entries but does not itself disclose new ownership figures or changes.

Securities Compliance Analyst

TL;DR: A routine regulatory correction with minimal market impact; ensures record accuracy for disclosure compliance.

The document serves to correct the public record by withdrawing a previously announced TR-1 as erroneous and pointing to the correct TR-1 issued on 21 August 2025. From a compliance perspective, promptly issuing such a correction reduces disclosure risk. The filing does not provide financial metrics, transaction details, or implications for governance beyond the notice itself.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Holding(s) in Company

28 August 2025

On 27 August 2025, AstraZeneca PLC (the Company) was notified by The Capital Group Companies, Inc. (Capital Group) that the TR-1 notification it submitted to the Company on 25 August 2025, and which was subsequently announced by the Company on 26 August 2025, was provided in error.

Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 26 August 2025 and instead refer to the TR-1 notification in relation to Capital Group announced by the Company on 21 August 2025, which is available under RNS No. 2435W / at:

https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1979582&culture=en-GB&val=638918832221613810

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 August 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) announce in this Form 6-K?

The filing states that a TR-1 notification announced on 26 August 2025 was provided in error and should be disregarded; investors should refer to the TR-1 announced on 21 August 2025.

Does this Form 6-K disclose any new shareholding figures for AZN?

No. The document does not provide new ownership numbers; it only corrects which prior TR-1 disclosure is valid.

Who submitted the TR-1 notification referenced in the correction?

The filing identifies The Capital Group Companies, Inc. as the notifier of the TR-1 that was referenced.

Where can I find the correct TR-1 notification for Capital Group referenced by AstraZeneca?

AstraZeneca directs readers to the TR-1 announced on 21 August 2025 available at the RNS link included in the filing.

Does the correction indicate any regulatory or legal action?

No. The filing is an administrative correction and does not mention any regulatory or legal actions.